These findings indicate that blood-based p-tau217 can be measured either with plasma or serum, enabling more hospital systems to adopt it for early and accurate detection of Alzheimer's disease.

We found that plasma and serum p-tau217 showed equivalent clinical accuracies to identify Alzheimer’s disease. Yet, there were a few technical differences between plasma and serum p-tau217 that need to be accounted for.

Across two human cohorts, we collected blood and processed aliquots from the same draw separately into EDTA plasma and serum.
We compared plasma and serum levels of p-tau217 using four assays evaluated (three commercial and a new one developed in the Karikari Lab)

Why compare Serum vs. Plasma? Most available assays use plasma for p-tau217 measurement, but some clinical systems prefer serum. As the field moves this blood biomarker into the clinic, validation of serum p-tau217 is necessary to ensure widespread use.

We are excited to join the growing neurodegenerative research community on BlueSky and look forward to being able to see all the great work our colleagues are doing worldwide and to share some of our findings with you all! #AlzheimersResearch #science #UPITT